Skip to main content
All lobbying filings

INDEPENDENT PHARMACY COOPERATIVE

Lobbying for INDEPENDENT PHARMACY COOPERATIVE · National GPO and drug distribution services for independent pharmacies.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Wisconsin · House · Senate · $60,000.00 expenses · posted Apr 16, 2026

Official filing document

 Bills named in this filing 12
  • S 526
    Pharmacy Benefit Manager Transparency Act of 2025
  • S 527
    Prescription Pricing for the People Act of 2025
  • S 882
    Patients Before Middlemen Act
  • HR 4317
    PBM Reform Act of 2025
  • S 3345
    PBM Price Transparency and Accountability Act
  • HR 3164
    Ensuring Community Access to Pharmacist Services Act
  • S 2426
    Equitable Community Access to Pharmacist Services Act
  • HR 6609
    Pharmacists Fight Back in Medicare and Medicaid Act
  • HR 6610
    Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
  • HR 5256
    340B ACCESS Act
  • S 3822
    Break Up Big Medicine Act
  • S 927
    Protecting Pharmacies in Medicaid Act
 Lobbying activity 1
Pharmacy

IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "The Ensuring Community Access to Pharmacists Services (ECAPS) Act IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC supports the Continuing Appropriations Act 2026 (Medicare Part D PBM Reform provisions). IPC supports the Break Up Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem